Edition:
United States

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

4.44USD
12:21pm EDT
Change (% chg)

$0.17 (+3.98%)
Prev Close
$4.27
Open
$4.35
Day's High
$4.48
Day's Low
$4.27
Volume
60,151
Avg. Vol
542,067
52-wk High
$7.21
52-wk Low
$0.98

Chart for

About

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $80.42
Shares Outstanding(Mil.): 71.17
Dividend: --
Yield (%): --

Financials

  ARQL.OQ Industry Sector
P/E (TTM): -- 86.20 32.69
EPS (TTM): -0.39 -- --
ROI: -91.39 0.73 14.32
ROE: -120.33 1.82 16.04

BRIEF-Arqule Files Prospectus Related To Seconday Offering Of Up To 10.6 Mln Shares

* ARQULE INC FILES PROSPECTUS RELATED TO OFFERING UP TO 10.6 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source http://bit.ly/2IOmvpZ Further company coverage:

May 17 2018

BRIEF-Arqule Reports Q1 Loss Per Share Of $0.07

* Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S

May 07 2018

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

Apr 17 2018

Competitors

Earnings vs. Estimates